{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T06:13:33Z","timestamp":1772604813690,"version":"3.50.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T00:00:00Z","timestamp":1674086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["418059"],"award-info":[{"award-number":["418059"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011513","name":"Ataxia Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011513","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002243","name":"National Ataxia Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002243","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The small size of CjCas9 can make easier its vectorization for <jats:italic>in vivo<\/jats:italic> gene therapy. However, compared to the SpCas9, the CjCas9 is, in general, less efficient to generate indels in target genes. The factors that affect its efficacity are not yet determined. We observed that the CjCas9 protein expressed in HEK293T cells after transfection of this transgene under a CMV promoter was much lower than the SpCas9 protein in the same conditions. We thus evaluated the effect of proteasome inhibitors on CjCas9 protein stability and its efficiency on <jats:italic>FXN<\/jats:italic> gene editing. Western blotting showed that the addition of MG132 or bortezomib, significantly increased CjCas9 protein levels in HEK293T and HeLa cells. Moreover, bortezomib increased the level of CjCas9 protein expressed under promoters weaker than CMV such as CBH or EFS but which are specific for certain tissues. Finally, ddPCR quantification showed that bortezomib treatment enhanced CjCas9 efficiency to delete GAA repeat region of <jats:italic>FXN<\/jats:italic> gene in HEK293T cells. The improvement of CjCas9 protein stability would facilitate its used in CRISPR\/Cas system.<\/jats:p>","DOI":"10.1371\/journal.pone.0280353","type":"journal-article","created":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T18:32:30Z","timestamp":1674153150000},"page":"e0280353","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Small-molecule inhibitors of proteasome increase CjCas9 protein stability"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7515-8297","authenticated-orcid":true,"given":"Pouir\u00e9","family":"Yam\u00e9ogo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Majeau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6908-4570","authenticated-orcid":true,"given":"Cedric Happi","family":"Mbakam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9404-9195","authenticated-orcid":true,"given":"Jacques P.","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2023,1,19]]},"reference":[{"issue":"11","key":"pone.0280353.ref001","first-page":"1014","article-title":"The CRISPR system can correct or modify the expression of genes responsible for hereditary diseases","volume":"31","author":"JP Tremblay","year":"2015","journal-title":"Med Sci (Paris)."},{"issue":"9","key":"pone.0280353.ref002","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/nbt.2647","article-title":"DNA targeting specificity of RNA-guided Cas9 nucleases","volume":"31","author":"PD Hsu","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"11","key":"pone.0280353.ref003","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.ymthe.2018.08.010","article-title":"CRISPR-Induced Deletion with SaCas9 Restores Dystrophin Expression in Dystrophic Models In Vitro and In Vivo","volume":"26","author":"BL Duchene","year":"2018","journal-title":"Mol Ther"},{"issue":"4","key":"pone.0280353.ref004","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.molcel.2018.12.003","article-title":"A Compact, High-Accuracy Cas9 with a Dinucleotide PAM for In Vivo Genome Editing","volume":"73","author":"A Edraki","year":"2019","journal-title":"Mol Cell"},{"key":"pone.0280353.ref005","article-title":"CRISPR-SCReT (CRISPR-Stop Codon Read Through) method to control Cas9 expression for gene editing","author":"P Yameogo","year":"2021","journal-title":"Gene Ther"},{"key":"pone.0280353.ref006","doi-asserted-by":"crossref","first-page":"14500","DOI":"10.1038\/ncomms14500","article-title":"In vivo genome editing with a small Cas9 orthologue derived from Campylobacter jejuni","volume":"8","author":"E Kim","year":"2017","journal-title":"Nature communications"},{"issue":"1","key":"pone.0280353.ref007","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.cell.2020.03.023","article-title":"CRISPR-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors","volume":"181","author":"D Wang","year":"2020","journal-title":"Cell"},{"issue":"11","key":"pone.0280353.ref008","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1038\/mt.2010.170","article-title":"Proteasome inhibitors enhance gene delivery by AAV virus vectors expressing large genomes in hemophilia mouse and dog models: a strategy for broad clinical application","volume":"18","author":"PE Monahan","year":"2010","journal-title":"Mol Ther"},{"issue":"1","key":"pone.0280353.ref009","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/mt.2009.255","article-title":"Effect of genome size on AAV vector packaging","volume":"18","author":"Z Wu","year":"2010","journal-title":"Mol Ther"},{"issue":"3685","key":"pone.0280353.ref010","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1126\/science.149.3685.754","article-title":"Adenovirus-Associated Defective Virus Particles","volume":"149","author":"RW Atchison","year":"1965","journal-title":"Science"},{"issue":"6","key":"pone.0280353.ref011","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.ymthe.2018.03.018","article-title":"Functional Rescue of Dystrophin Deficiency in Mice Caused by Frameshift Mutations Using Campylobacter jejuni Cas9","volume":"26","author":"T Koo","year":"2018","journal-title":"Mol Ther"},{"key":"pone.0280353.ref012","doi-asserted-by":"crossref","first-page":"570917","DOI":"10.3389\/fncel.2020.570917","article-title":"Comparison of CRISPR\/Cas Endonucleases for in vivo Retinal Gene Editing","volume":"14","author":"F Li","year":"2020","journal-title":"Front Cell Neurosci"},{"issue":"6","key":"pone.0280353.ref013","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1101\/gr.171322.113","article-title":"Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins","volume":"24","author":"S Kim","year":"2014","journal-title":"Genome Res"},{"issue":"12","key":"pone.0280353.ref014","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.bbadis.2008.10.002","article-title":"Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection","volume":"1782","author":"NB Nedelsky","year":"2008","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"pone.0280353.ref015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.15430\/JCP.2018.23.4.153","article-title":"Regulation of Protein Degradation by Proteasomes in Cancer","volume":"23","author":"HH Jang","year":"2018","journal-title":"J Cancer Prev"},{"issue":"1","key":"pone.0280353.ref016","doi-asserted-by":"crossref","first-page":"e54282","DOI":"10.1371\/journal.pone.0054282","article-title":"Stability of zinc finger nuclease protein is enhanced by the proteasome inhibitor MG132","volume":"8","author":"S Ramakrishna","year":"2013","journal-title":"PLoS One"},{"key":"pone.0280353.ref017","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.nbd.2014.12.011","article-title":"Highly specific ubiquitin-competing molecules effectively promote frataxin accumulation and partially rescue the aconitase defect in Friedreich ataxia cells","volume":"75","author":"A Rufini","year":"2015","journal-title":"Neurobiol Dis"},{"issue":"6","key":"pone.0280353.ref018","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1634\/theoncologist.8-6-508","article-title":"Velcade: U.S. FDA approval for the treatment of multiple myeloma progressing on prior therapy","volume":"8","author":"RC Kane","year":"2003","journal-title":"Oncologist"},{"issue":"22","key":"pone.0280353.ref019","doi-asserted-by":"crossref","first-page":"e168","DOI":"10.1093\/nar\/gku936","article-title":"Easy quantitative assessment of genome editing by sequence trace decomposition","volume":"42","author":"EK Brinkman","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"pone.0280353.ref020","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/crispr.2018.0036","article-title":"Improving CRISPR-Cas9 Genome Editing Efficiency by Fusion with Chromatin-Modulating Peptides","volume":"2","author":"X Ding","year":"2019","journal-title":"CRISPR J"},{"issue":"2","key":"pone.0280353.ref021","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1021\/acschembio.7b00831","article-title":"Protein Inhibitors of CRISPR-Cas9","volume":"13","author":"J. Bondy-Denomy","year":"2018","journal-title":"ACS Chem Biol"},{"key":"pone.0280353.ref022","doi-asserted-by":"crossref","first-page":"14370","DOI":"10.1038\/ncomms14370","article-title":"Rapid and tunable method to temporally control gene editing based on conditional Cas9 stabilization","volume":"8","author":"S Senturk","year":"2017","journal-title":"Nat Commun"},{"key":"pone.0280353.ref023","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1016\/j.csbj.2019.07.015","article-title":"Drug Inducible CRISPR\/Cas Systems","volume":"17","author":"J Zhang","year":"2019","journal-title":"Comput Struct Biotechnol J"},{"issue":"6","key":"pone.0280353.ref024","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061447","article-title":"Valproic Acid Significantly Improves CRISPR\/Cas9-Mediated Gene Editing","volume":"9","author":"H Park","year":"2020","journal-title":"Cells"},{"key":"pone.0280353.ref025","article-title":"Small-molecule inhibitors of histone deacetylase improve CRISPR-based adenine base editing","author":"HR Shin","year":"2021","journal-title":"Nucleic Acids Res"},{"issue":"2","key":"pone.0280353.ref026","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1093\/nar\/gkz1136","article-title":"Inhibition of histone deacetylase 1 (HDAC1) and HDAC2 enhances CRISPR\/Cas9 genome editing","volume":"48","author":"B Liu","year":"2020","journal-title":"Nucleic Acids Res"},{"issue":"4","key":"pone.0280353.ref027","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.cell.2019.04.009","article-title":"A High-Throughput Platform to Identify Small-Molecule Inhibitors of CRISPR-Cas9","volume":"177","author":"B Maji","year":"2019","journal-title":"Cell"},{"issue":"8","key":"pone.0280353.ref028","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tibs.2018.06.005","article-title":"Quality Control in the Endoplasmic Reticulum: Crosstalk between ERAD and UPR pathways","volume":"43","author":"J Hwang","year":"2018","journal-title":"Trends Biochem Sci"},{"issue":"6","key":"pone.0280353.ref029","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.molcel.2017.02.007","article-title":"Crystal Structure of the Minimal Cas9 from Campylobacter jejuni Reveals the Molecular Diversity in the CRISPR-Cas9 Systems","volume":"65","author":"M Yamada","year":"2017","journal-title":"Mol Cell"},{"key":"pone.0280353.ref030","doi-asserted-by":"crossref","first-page":"761","DOI":"10.3389\/fonc.2019.00761","article-title":"Proteasomes and Several Aspects of Their Heterogeneity Relevant to Cancer","volume":"9","author":"AV Morozov","year":"2019","journal-title":"Front Oncol"},{"key":"pone.0280353.ref031","article-title":"Design of experiments as a decision tool for cell therapy manufacturing","author":"E Lee","year":"2022","journal-title":"Cytotherapy"},{"issue":"19","key":"pone.0280353.ref032","doi-asserted-by":"crossref","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","article-title":"Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species","volume":"184","author":"M Tabebordbar","year":"2021","journal-title":"Cell"},{"issue":"6","key":"pone.0280353.ref033","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1128\/JVI.02309-08","article-title":"Enhancement of adeno-associated virus infection by mobilizing capsids into and out of the nucleolus","volume":"83","author":"JS Johnson","year":"2009","journal-title":"J Virol"},{"issue":"1","key":"pone.0280353.ref034","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/gt.2011.211","article-title":"Zinc-finger nuclease-mediated gene correction using single AAV vector transduction and enhancement by Food and Drug Administration-approved drugs","volume":"20","author":"BL Ellis","year":"2013","journal-title":"Gene Ther"},{"issue":"4","key":"pone.0280353.ref035","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10565-013-9248-z","article-title":"Mechanisms of proteasome inhibitor-induced cytotoxicity in malignant glioma","volume":"29","author":"PJ Vlachostergios","year":"2013","journal-title":"Cell Biol Toxicol"},{"issue":"21","key":"pone.0280353.ref036","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222111595","article-title":"Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism","volume":"22","author":"J Wang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"pone.0280353.ref037","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1146\/annurev-pharmtox-010919-023603","article-title":"Proteasome Inhibitor Drugs","volume":"60","author":"LD Fricker","year":"2020","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"6","key":"pone.0280353.ref038","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1053\/j.seminoncol.2018.01.004","article-title":"Proteasome inhibitors: structure and function","volume":"44","author":"AT Nunes","year":"2017","journal-title":"Semin Oncol"},{"key":"pone.0280353.ref039","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.trsl.2018.03.002","article-title":"Next-generation proteasome inhibitors for cancer therapy","volume":"198","author":"JE Park","year":"2018","journal-title":"Transl Res"},{"issue":"8","key":"pone.0280353.ref040","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.celrep.2017.01.079","article-title":"E3 Ligase RNF126 Directly Ubiquitinates Frataxin, Promoting Its Degradation: Identification of a Potential Therapeutic Target for Friedreich Ataxia","volume":"18","author":"M Benini","year":"2017","journal-title":"Cell Rep"},{"issue":"7","key":"pone.0280353.ref041","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/hmg\/ddq566","article-title":"Preventing the ubiquitin-proteasome-dependent degradation of frataxin, the protein defective in Friedreich\u2019s ataxia","volume":"20","author":"A Rufini","year":"2011","journal-title":"Hum Mol Genet"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0280353","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,19]],"date-time":"2023-01-19T18:32:55Z","timestamp":1674153175000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0280353"}},"subtitle":[],"editor":[{"given":"Arunava","family":"Roy","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2023,1,19]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,1,19]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0280353","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,19]]}}}